Elevated plasma F2-isoprostane levels in schizophrenia.

Area of Science:

• Neuroscience
• Biochemistry
• Psychiatry

Background:

• Schizophrenia is a severe psychiatric disorder linked to increased morbidity, mortality, and accelerated aging.
• Oxidative stress is implicated in schizophrenia, but systemic markers like plasma F2-isoprostanes have been understudied.
• This study is the first to measure plasma F2-isoprostane levels, a key indicator of in vivo oxidative stress, in individuals with schizophrenia.

Purpose of the Study:

• To investigate systemic oxidative stress by comparing plasma F2-isoprostane levels in schizophrenia patients and healthy controls.
• To explore associations between F2-isoprostane levels and clinical factors including psychopathology, executive function, BMI, gender, and medical comorbidities.

Main Methods:

• Plasma F2-isoprostane levels were measured in 134 stable schizophrenia outpatients and 120 age- and gender-matched healthy comparison subjects.
• Sociodemographic, clinical, and anthropometric data were collected for all participants.
• Statistical analyses, including linear models, were used to compare groups and assess correlations.

Main Results:

• Plasma F2-isoprostane levels were significantly higher in the schizophrenia group compared to healthy controls.
• Higher F2-isoprostane levels were observed in women and individuals with higher BMI within both groups.
• F2-isoprostane levels correlated with BMI, physical functioning, and medical comorbidity, but not with psychopathology or executive function.

Conclusions:

• The findings confirm increased systemic oxidative stress in schizophrenia, aligning with evidence of accelerated aging and higher morbidity/mortality.
• The significant influence of gender and BMI on oxidative stress markers warrants further investigation in schizophrenia.
• Elevated F2-isoprostanes may serve as a biomarker for oxidative stress contributing to the pathophysiology of schizophrenia.